Premature senescence activation in DLD-1 colorectal cancer cells through adjuvant therapy to induce a miRNA profile modulating cellular death

SERGIU CHIRA¹, LAJOS RADULY¹,², CORNELIA BRAICU¹, ANCUTA JURJ¹, ROXANA COIOCNEANU-PETRIC¹, LAURA POP¹, VALENTINA PILECKI¹, CALIN IONESCU³,⁴ and IOANA BERINDAN-NEAGOE¹,⁵,⁶

¹Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj-Napoca; ²Department of Pathophysiology, Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine, 400372 Cluj-Napoca; ³Department of Surgery, Iuliu Hatieganu University of Medicine and Pharmacy, 40015 Cluj-Napoca; ⁴Department of Surgical, Municipal Clinical Hospital; ⁵MEDFUTURE Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj-Napoca; ⁶Department of Functional Genomics and Experimental Pathology, Oncological Institute ‘Prof. Dr. Ion Chiricuţă’, 400015 Cluj-Napoca, Romania

Received November 12, 2017; Accepted February 16, 2018

DOI: 10.3892/etm.2018.6324

Abstract. Cancer, and particularly colon cancer, is associated with an increasing number of cases resistant to chemotherapy. One approach to overcome this, and to improve the prognosis and outcome of patients, is the use of adjuvant therapy alongside the standard chemotherapy regiment. In the present study, the effect of deuterium-depleted water (DDW) as a potential modulator of adjuvant therapy on DLD-1 colorectal cancer models was assessed. A number of functionality assays were performed, including MTT, apoptosis and autophagy, and mitochondrial activity and senescence assays, in addition to assessing the capacity to modify the pattern of released miRNA via microarray technology. No significant effect on cell viability was identified, but an increase in mitochondrial activity and a weak pro-apoptotic effect were observed in the treated DLD-1 cells cultured in DDW-prepared medium compared with those grown in standard conditions (SC). Furthermore, the findings revealed the capacity of DDW medium to promote senescence to a higher degree compared with SC. The exosome-released miRNA pattern was significantly modified for the cells maintained in DDW compared with those maintained in SC. These findings suggest that DDW may serve as an adjuvant treatment; however, a better understanding of the underlying molecular mechanism of action will be useful for developing novel and efficient therapeutic strategies, in which the transcriptomic pattern serves an important role.

Introduction

Cancer represents the second greatest cause of mortality in developing countries, for which the chemotherapy is the most effective treatment. However, its efficiency is limited by the ability of cancer cells to acquire resistance to the treatment regimen, which accounts for ~90% of failures (1,2). Drug resistance is currently considered the most notable challenge in cancer therapy. This resistance may be determined by genetic and epigenetic mechanisms as a response to different biochemical processes, and also by changes in drug levels during the course of treatment (3). One potential approach to overcome this, while improving the prognostic and outcome of patients, is the use of adjuvant therapy in addition to the standard chemotherapy regimen.

Deuterium is a natural and stable isotope of hydrogen, which is found in the Earth's atmosphere at a concentration of 144-155 ppm (4). An increase in deuterium concentration leads to the formation of heavy water, which has different physical and chemical proprieties compared with normal water (5). This heavy water has detrimental effects on living organisms; ingestion can cause sterility, while high concentrations of deuterium can result in mortality via modification of the mitotic cycle and cell membrane function (6). Therefore it is presumable that deuterium-depleted water (DDW) may have beneficial effects by interfering cell metabolism and the overall function of living cells (7,8).

A number of previous studies have explored the effects of deuterium-depletion on cell proliferation, on both in vitro and in vivo cancer models. A study on the A549 lung carcinoma cell line demonstrated that deuterium-depleted water leads to a reduction in cell proliferation between 10 and 72 h of
exposure, with a peak of cellular structural changes occurring at 72 h of exposure (9). This effect of tumor inhibition has also been confirmed on orthotopic models of BALB/c mice (9) and human patients with lung cancer (10). This tumor regression may be correlated with a reduction in the expression levels of several oncogenes, such as KRAS, B cell lymphoma 2 (Bcl2) or c-Myc, as previously reported (10), suggesting apoptosis as the potential mechanism of tumor inhibition by DDW in cell lines that overexpress Bcl2, a process also observed in pancreatic cell lines (11). Besides the pro-apoptotic effect, DDW seems to have an inhibitory effect on migration and invasion by downregulating proliferating cell nuclear antigen and matrix metalloproteinase 9 previous in nasopharyngeal cell carcinoma (12). Additionally, this study indicated an induction of NAD(P)H quinone dehydrogenase 1 expression, which is a protein that regulates different cell cycle factors, such as cyclin D1, p21 and c-Myc.

Free or exosome-released microRNA (miRNA or miR) patterns may be used as valuable biomarkers for defining physiological and pathological processes of cell subpopulation (13-16). Previous studies have emphasized the important role of the manipulation of miRNA profiles (17,18), which is considered as a novel approach for colon cancer prevention, chemotheraphy and avoidance of drug resistance related mechanisms (19,20). Therefore, in the present study the impact of DDW on the capacity to alter released miRNA patterns was evaluated in colorectal cancer cells, along with a set of preliminary functionality tests in order to evaluate the utility of DDW as an adjuvant in colorectal cancer therapy.

Materials and methods

Materials and cell lines. Powdered RPMI-1640 medium supplemented with glutamine, liquid RPMI-1640, fetal bovine serum (FBS), PBS, penicillin-streptomycin 100X and trypsin-EDTA solutions were obtained from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Dimethyl sulfoxide (DMSO) and MTI were obtained from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany). DLD-1 (colorectal carcinoma) cell line was obtained from American Type Culture Collection (Manassas, VA, USA). Oxaliplatin was obtained from Fresenius Kabi Asia-Pacific, Ltd. (Wanchai, Hong Kong) and 5-fluorouracil (5-FU) was obtained from Ebeewe Pharma GmbH (Unterach, Austria). DDW was provided by Qlarivia; Micro System SRL (Bucharest, Romania) with 25±5 ppm D/(D+H), obtained by vacuum distillation.

MTT cell viability assay. For assessing the cytotoxicity of selected chemotherapeutic agents, DLD-1 cell line was maintained for 64 passages in standard conditions (SC) and for 66 passages in medium with low concentration of deuterium (DDW). A total of 10,000 DLD-1 colorectal cancer cells/well were plated in 96-well plates in RPMI-1640 medium supplemented with 10% FBS, 2 mM glutamine and 1X penicillin-streptomycin for SC cell culture, and 10,000 DLD-1 colorectal cancer cells/well were plated in 96-well plates in filter-sterilized RPMI-1640 medium powder (supplemented with glutamine) prepared with DDW supplemented with 10% FBS and 1X penicillin-streptomycin for DDW cell culture. Cells were incubated at 37°C in a 5% CO₂ atmosphere for 24 h and the cytostatic agents were subsequently applied separately in triplicate at concentrations of 1, 2, 4, 5, 8, 10 and 12 µM for 5-FU, and 2, 4, 6, 8, 10, 12, 14 and 20 µM for oxaliplatin. At 24, 48 and 72 h following treatment, the medium was discarded, and the adherent cells were treated with 150 µl MTT solution (1 mg/ml). Following 1 h incubation at 37°C, the formazan crystals were solubilized with 100 µl DMSO and the viability of the cells was assessed at 492 nm wavelength using a microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).

Computation of inhibition constant 50 (IC₅₀). The response curves to cytostatic drugs were generated from the MTT data and computed using MasterPlex Readerfit software (trial version 2.0.0.73; MiraiBio Group of Hitachi Solutions America, Ltd., San Francisco, CA, USA), and IC₅₀ values were determined based on the response curves.

Total RNA extraction from exosome-released medium. The exosomes released from cells cultured in SC and DDW cell culture medium without 5-FU or oxaliplatin were precipitated from 4 ml cell culture media using Total Exosome Isolation Reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol. Subsequently the precipitated exosomal fraction was used for extraction of total RNA using a Plasma/Serum Circulating and Exosomal RNA Purification kit (Slurry Format; Norgen Biotek Corp., Thorold, ON, Canada) for the cells maintained in SC and those maintained in DDW-prepared medium.

Microarray evaluation, data analysis and identification of differentially expressed miRNAs released in cell culture medium. The microarray experiment was conducted using the Human miRNA Microarray Kit (release 21.0; format, 8x60K slides; Agilent Technologies, Inc., Santa Clara, CA, USA). The miRNA Labeling and Hybridization kit was used according to the manufacturer’s protocol, together with the Complete Labeling and Hybridization kit (both Agilent Technologies, Inc.) using 100 ng total RNA from 2 samples of cells grown in SC and 2 samples cultivated in DDW-prepared medium, labeled with pCp-Cy3 and purified with MicroBioSpin 6 Columns (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Slides were hybridized for 20 h at 54°C, washed with Agilent washing solution 1 and 2, and scanned using the Agilent Microarray Scanner G2565BA (Agilent Technologies, Inc.).

Samples were grouped according to duplicates, and preliminary data analysis was performed using Feature Extraction Software (version 10.7; Agilent Technologies, Inc.). Differential analysis of miRNA expression was performed using GeneSpring GX version 12.6.1 software (Agilent Technologies, Inc.), using P≤0.05 and -1.5≤ fold change (FC) ≥1.5. For the integration of the altered miRNA patterns as an effect of DDW exposure in biological mechanisms, the NCBI Database was used (www.ncbi.nlm.nih.gov).

Ingenuity Pathway Analysis (IPA®; Qiagen, Inc., Valencia, CA, USA) is a valuable bioinformatics tool that was used for the identification of the most relevant altered pathways based on the identified altered transcriptomic profile in the cells cultured in DDW conditions compared with those in SC conditions. It contains a database with >302 metabolic networks and
360 signaling pathways used for the altered miRNA signature, the miRNAs were scored on the significance of their overlap with these networks and pathways.

The Cancer Genome Atlas (TCGA) data analysis for colorectal cancer. The extent to which the expression of microRNAs is prone to modification as a result of treatment was subsequently evaluated. TCGA was used and differential analysis was performed using the miRNA expression data for patients with colorectal cancer, which was downloaded from the University of California Santa Cruz genome browser (https://genome.ucsc.edu). The data for colon adenocarcinoma, which consisted of 433 tumor samples and 8 normal samples, was combined with expression data for rectum adenocarcinoma, which consisted of 162 tumor tissues and 3 normal tissues, to obtain the colorectal cancer cohort. Using GeneSpring GX software (version 14.9; Agilent Technologies, Inc.), differential expression analysis was performed, and by applying filters of using P≤0.05 and ‑1.5≤FC≥1.5, a list containing the most upregulated and downregulated microRNAs between tumors and normal tissues was generated, as described previously (21-23).

Generation of Venn diagram. Using the obtained TCGA miRNA data the Venn diagram was generated using the online tool Venny version 2.1 (http://bioinfogp.cnb.csic.es/tools/venny/) and indicated the commonly or inversely regulated transcripts in DDW-treated cells.

Assessing apoptosis via fluorescence microscopy tetramethylrhodamine, ethyl ester (TMRE)/Hoechst double staining. Evaluation of apoptosis was performed using a Multi-Parameter Apoptosis kit (Cayman Chemical Company, Ann Arbor, MI, USA), according to the manufacturer's protocol. Cells from the SC and DDW groups were analyzed at UV wavelength (560/595 nm) for Hoechst and TMRE staining using a Mitochondrial Membrane Potential Assay kit (cat no. 701310; Cayman Chemical Company) according to the manufacturer's protocol, and Olympus IX71 microscope (Olympus Corporation, Tokyo, Japan) at a magnification of x20. Hoechst is a cell permeable dye for the nuclei, independent of the cell membrane status, whereas TMRE dye allows the evaluation of mitochondrial function by assessing the membrane potential, which is lost in cells entering apoptosis (24-26). Cell apoptosis was evaluated at 48 h of exposure to 5-FU and oxaliplatin at the IC_{50} concentration.

Evaluation of senescence. For senescence evaluation of cells cultured in SC and DDW conditions, the Senescence Detection kit (Abcam, Cambridge, UK) was used according to the manufacturer's protocol. The kit detects β-galactosidase, which is overexpressed in senescent cells (27). Cells were visualized in both cases using an Olympus IX71 microscope (magnification, x20).

Results

Evaluation of the altered miRNA expression profiles. Differential miRNA expression profiles in the case of colorectal cells maintained in DDW vs. those maintained in SC were evaluated using miRNA labeling and hybridization, and

### Table I. The altered miRNA pattern for the case of deuterium-depleted water-maintained cells vs. those maintained in standard conditions.

| Systematic name | Fold change | Corrected P-value |
|-----------------|-------------|-------------------|
| hsa-miR-4261    | -22.7086    | 2.16E-04          |
| hsa-miR-3912-5p | -22.0231    | 2.16E-04          |
| hsa-miR-4711-3p | -18.467     | 2.16E-04          |
| hsa-miR-362-5p  | -16.8774    | 0.001651          |
| hsa-miR-3923    | -16.6997    | 0.001231          |
| hsa-miR-664a-3p | -16.3672    | 0.001651          |
| hsa-miR-34b-5p  | -16.0323    | 0.008314          |
| hsa-miR-136-5p  | -14.7967    | 0.002438          |
| hsa-miR-5007-5p | -13.0422    | 2.16E-04          |
| hsa-miR-4317    | -13.0337    | 6.44E-04          |
| hsa-miR-193b-5p | -12.6629    | 6.44E-04          |
| hsa-miR-4700-5p | -12.6546    | 0.021906          |
| hsa-miR-125a-5p | -12.1643    | 0.001253          |
| hsa-miR-936     | -11.01      | 0.014825          |
| hsa-miR-6516-5p | -10.4295    | 0.012692          |
| hsa-miR-4488    | -10.3318    | 0.012692          |
| hsa-miR-545-3p  | -9.28502    | 0.013747          |
| hsa-miR-4715-5p | -9.23226    | 0.008749          |
| hsa-miR-4468    | -7.60702    | 3.74E-04          |
| hsa-miR-32-5p   | -5.34052    | 0.011851          |
| hsa-miR-6872-3p | -4.00105    | 0.017607          |
| hsa-miR-4291    | -2.81713    | 0.03264           |
| hsa-miR-1260b   | -2.52161    | 0.006656          |
| hsa-miR-1233-5p | -2.2066     | 0.022847          |
| hsa-miR-3684    | -2.15719    | 0.013747          |
| hsa-miR-3976    | -2.12003    | 0.042139          |
| hsa-miR-182-5p  | -2.11261    | 0.010321          |
| hsa-miR-5100    | -2.11064    | 0.014468          |
| hsa-miR-1260a   | -2.08488    | 0.00429           |
| hsa-miR-660-3p  | -2.06228    | 0.03624           |
| hsa-miR-3064-5p | -2.03183    | 0.021906          |
| hsa-miR-6717-5p | -2.0278     | 0.017607          |
| hsa-miR-6788-5p | -1.96362    | 0.009607          |
| hsa-miR-7114-5p | -1.95488    | 0.014468          |
| hsa-miR-18b-5p  | -1.9179     | 0.012687          |
| hsa-miR-324-5p  | -1.8771     | 0.034038          |
| hsa-miR-1273g-3p| -1.87346    | 0.033338          |
| hsa-miR-6131    | -1.8712     | 0.019085          |
| hsa-miR-921     | -1.87005    | 0.037554          |
| hsa-miR-6826-5p | -1.85113    | 0.014468          |
| hsa-miR-7159-5p | -1.83784    | 0.03967           |
| hsa-miR-4753-5p | -1.80366    | 0.014468          |
| hsa-miR-320b    | -1.74454    | 0.019579          |
| hsa-miR-126-3p  | -1.73136    | 0.045633          |
| hsa-miR-5196-5p | -1.72965    | 0.033735          |
| hsa-miR-6872-5p | -1.65159    | 0.024325          |
| hsa-miR-211-3p  | -1.61236    | 0.021906          |
| hsa-miR-6875-5p | -1.60393    | 0.014468          |
| hsa-miR-320e    | -1.57832    | 0.012692          |
Table I. Continued.

| Systematic name | Fold change | Corrected P-value |
|------------------|-------------|------------------|
| hsa-miR-146a-5p  | -1.57515    | 0.033735         |
| hsa-miR-23a-3p   | -1.57461    | 0.034732         |
| hsa-let-7d-5p    | -1.57108    | 0.037564         |
| hsa-miR-6085     | -1.57099    | 0.012896         |
| hsa-miR-23b-3p   | -1.55252    | 0.034038         |
| hsa-miR-3907     | -1.53592    | 0.012692         |
| hsa-miR-3650     | -1.52958    | 0.013747         |
| hsa-miR-3689b-3p | -1.52555    | 0.033715         |
| hsa-miR-4286     | -1.52084    | 0.034127         |
| hsa-miR-539-5p   | -1.51706    | 0.026802         |
| hsa-miR-6777-3p  | 12.35759    | 0.001651         |
| hsa-miR-1247-5p  | 10.66176    | 0.012687         |
| hsa-miR-5008-3p  | 10.36788    | 0.017607         |
| hsa-miR-6870-3p  | 10.21028    | 0.010321         |
| hsa-miR-4508     | 10.0584     | 0.014468         |
| hsa-miR-373-5p   | 8.170245    | 0.04109          |
| hsa-miR-6812-3p  | 7.939796    | 0.042139         |
| hsa-let-7b-3p    | 7.565567    | 0.034732         |
| hsa-miR-326      | 7.435405    | 0.027191         |
| hsa-miR-375      | 3.686158    | 0.012687         |
| hsa-miR-6726-5p  | 3.444442    | 0.001231         |
| hsa-miR-3934-5p  | 3.160403    | 0.009522         |
| hsa-miR-1236-5p  | 2.984447    | 0.001231         |
| hsa-miR-887-3p   | 2.868279    | 0.033735         |
| hsa-miR-135a-3p  | 2.717766    | 0.03624          |
| hsa-miR-4634     | 2.264031    | 0.039541         |
| hsa-miR-718      | 2.204079    | 0.011618         |
| hsa-miR-422a     | 2.180337    | 0.033338         |
| hsa-miR-5585-3p  | 2.140601    | 0.024133         |
| hsa-miR-8089     | 2.08933     | 0.008314         |
| hsa-miR-6760-3p  | 2.02642     | 0.014468         |
| hsa-miR-615-3p   | 2.022371    | 0.033735         |
| hsa-miR-1181     | 1.971624    | 0.012687         |
| hsa-miR-4476     | 1.904539    | 0.026744         |
| hsa-miR-197-5p   | 1.886881    | 0.033715         |
| hsa-miR-6133     | 1.845085    | 0.012687         |
| hsa-miR-7846-3p  | 1.83585     | 0.017607         |
| hsa-miR-5787     | 1.829065    | 0.017607         |
| hsa-miR-6858-3p  | 1.826295    | 0.028224         |
| hsa-miR-4646-5p  | 1.779853    | 0.012687         |
| hsa-miR-630      | 1.766601    | 0.012687         |
| hsa-miR-3646     | 1.748758    | 0.011618         |
| hsa-miR-583      | 1.748449    | 0.017607         |
| hsa-miR-3679-5p  | 1.736775    | 0.033735         |
| hsa-miR-3622b-5p | 1.725885    | 0.014468         |
| hsa-miR-1185-2-3p| 1.654606    | 0.013747         |
| hsa-miR-4769-5p  | 1.653051    | 0.027191         |
| hsa-miR-6125     | 1.63833     | 0.013747         |
| hsa-miR-125a-3p  | 1.638016    | 0.033735         |
| hsa-miR-6068     | 1.636307    | 0.012687         |
| hsa-miR-4530     | 1.627722    | 0.029275         |

Table I. Continued.

| Systematic name | Fold change | Corrected P-value |
|------------------|-------------|------------------|
| hsa-miR-7107-5p  | 1.625659    | 0.033735         |
| hsa-miR-601      | 1.610057    | 0.012687         |
| hsa-miR-5703     | 1.598128    | 0.012692         |
| hsa-miR-3960     | 1.593793    | 0.012692         |
| hsa-miR-2861     | 1.537284    | 0.026802         |

miRNA/miR, microRNA; has, human.

Gene microarray evaluation. During data analysis using the specialized GeneSpring GX software, a cut-off value of -1.5≤FC≥1.5 and P<0.05 were considered, and were able to identify several transcripts with altered expression levels. In total, 105 transcripts with modified expression levels were identified, from which 46 were upregulated and 59 downregulated (Table I).

IPA® Network analysis. One of the aims of the present study was to evaluate the potential significance of altered miRNAs at the cellular and molecular level, mediated by DDW. IPA® analysis was performed for all miRNAs with an altered expression level for the assessment of the potential consequences by evaluating the networks; the principle of the gene network interactions were discussed in a previous study (28). Fig. 1 presents the integration of the altered miRNAs transcripts in with the highest significance score, including organismal injury and abnormalities, reproductive system disease, cancer (Fig. 1A), inflammatory diseases, the inflammatory response, organismal injury and abnormalities (Fig. 1B), and hematological diseases and hereditary disorders (Fig. 1C). The IPA® analysis also classified the altered miRNAs transcripts in terms of the most relevant diseases and biological function (Table II) or molecular functions (Table III) associated with DDW exposure.

Overlapping the altered miRNA pattern in DDW cells with TCGA data. Following TCGA data analysis, 163 miRNAs with altered expression levels were identified, 82 downregulated and 81 overexpressed (data not shown), considering a cut-off value of -1.5≤FC≥1.5 and P<0.05. A Venn diagram was constructed to identify the overlap of differentially regulated miRNAs obtained from the TCGA analysis for colorectal cancer, and the altered miRNA pattern obtained in the case of DLD-1 cells maintained in DDW vs. SC (Fig. 2).

DDW augmentation exhibits a weak pro-apoptotic effect in 5-FU and oxaliplatin treated DLD-1 cells. In order to determine whether DDW exhibits an adjuvant effect with 5-FU and oxaliplatin treatment on DLD-1 cells, cell viability was assessed via fluorescent microscopy using TMRE/Hoechst double staining. A common hallmark of apoptosis is the fragmentation and condensation of the nucleus.

In SC, no modifications of the nuclei were observed, however 5-FU treatment appears to be complemented by a decreased concentration of deuterium, with nuclei displaying...
slight structural modifications at 48 h following 5-FU exposure in the presence of DDW. The mitochondrial membrane potential remains unaffected (Fig. 3), with cells retaining their viability independent of deuterium concentrations (Table IV). By contrast, oxaliplatin treatment dissipates the mitochondrial membrane potential, with cells preserving the nucleic integrity (Fig. 3).

**Senescence in the cancer cell line DLD-1 is activated by DDW.** It was investigated whether maintaining the cells in DDW was able to induce senescence in the DLD-1 cell line, and therefore offer a novel platform for cancer therapeutics. DLD-1 cells were cultivated for 13 passages in SC or medium prepared with DDW, and were assessed for senescence via detection of β-galactosidase expression. The results indicated a low induction of senescence in cells cultivated in DDW medium compared with those maintained in SC (Fig. 4).

**Discussion**

Supplementation of cancer therapy with different adjuvant systems have been reported to induce notable benefits in a number cancer types, including colorectal cancer (29). The most well-known combination is that of oxaliplatin and 5-FU (30,31). These systems were developed to counteract the activated mechanisms that sustain tumor development, and particularly to avoid chemoresistance (32). Therefore, there is an urgent demand for evaluating novel adjuvant systems that may be implemented in clinical practice (29,32).

Chemoresistance has been associated with altered enzyme functions that are associated with microRNA maturation and primarily Dicer protein activity (19). Taking into account that chemoresistance is the main obstacle to the success of cancer treatment (1,2), the modulation of miRNA patterns may be used to avoid activation of drug resistance mechanism and to increase the therapeutic efficacy of classical chemotherapy (17,33).

In previous studies, deuterium depletion has been suggested to exhibit antiproliferative effects in cells exposed to low concentrations of this natural isotope of hydrogen (9,10) and to alter gene expression patterns in cancer cells (10). However, to the best of our knowledge, whether deuterium depletion influences the response of cancer cells to standard chemotherapy has not yet been investigated. Therefore, the aim of the present study was to investigate if deuterium concentration in the extracellular environment was able to modulate the response of DLD-1 colorectal cancer cells to the standard chemotherapeutic regimen. Oxaliplatin and 5-FU were selected as chemotherapeutic agents following National Comprehensive Cancer Network guidelines for colorectal...
Table II. Most significant diseases and functions altered in cells cultured in deuterium-depleted water vs. those maintained in standard conditions.

| Disease/function                        | P-value               | Molecules (n) |
|----------------------------------------|-----------------------|---------------|
| Inflammatory disease                   | 1.90E-02-3.95E-12     | 13            |
| Inflammatory response                  | 3.22E-02-3.95E-12     | 13            |
| Organismal injury and abnormalities    | 4.99E-02-3.95E-12     | 29            |
| Cancer                                 | 4.86E-02-3.59E-11     | 18            |

Table III. Most significant molecular functions from the miRNA pattern of cell cultured in deuterium-depleted water vs. those maintained in standard conditions.

| Name                                      | P-value               | Molecules (n) |
|-------------------------------------------|-----------------------|---------------|
| Cell-to-cell signaling and interaction    | 4.26E-03-8.72E-05     | 3             |
| Cellular function and maintenance         | 3.77E-02-8.72E-05     | 3             |
| Cell cycle                                | 3.91E-02-1.00E-03     | 3             |
| Cellular movement                         | 3.98E-02-1.62E-03     | 5             |
| Cell morphology                           | 2.53E-02-2.84E-03     | 1             |

cancer disease (34). In the present study, the effects of deuterium depletion in DLD-1 cancer cells subjected to 5-FU and Oxaliplatin treatment were assessed via microarray analysis to observe the differences in the molecular profile of miRNAs and, implicitly, of senescence and apoptosis genes modulated by these miRNAs.

Senescence represents a growth-arrest aging process that has been associated with degenerative pathologies in cells subjected to stress stimuli, leading to loss of function (35,36). Senescence has also been recognized as a potent...
antiproliferative mechanism for suppressing tumor growth and progression, and has been exploited as a potential anti-cancer target (37,38).

The capacity to regulate the miRNA pattern in normal, physiological conditions may have implications on cell fate. The modulation of released miRNA patterns may be considered as a promising strategy for increased therapeutic efficacy and particularly for avoiding the activation of drug resistance mechanisms. The modulation of miRNA-processing enzymes, Dicer1 and miRNAs may be important for senescence-related processes (39,40). The network presented in Fig. 1A, presents the key transcript Dicer1, which promotes senescence and cell differentiation (39,40). IPA® networks revealed that Dicer1 is targeted by several miRNAs, including miR-362-5p, miR-182-5p and miR-125-5p. The second network (Fig. 1B) is centered on Dicer1, Argonaute 2 and transcription factor E2F3, which are associated with selective autophagy (41), and are able to target cell cycle regulators, cell proliferation and apoptosis (42-44). Defective autophagy has been demonstrated to accelerate senescence (45), whereas the stimulation of autophagy may be an effective, novel therapeutic strategy, which may be used to increase the response to classical chemotherapy. The miRNA profiling data revealed two downregulated miRNAs (miR-23b and miR-193b) and one overexpressed transcript (let-7b) that are known to regulate autophagy, which was confirmed only partially by apoptosis and senescence evaluation with a microscope.

A previous study has demonstrated that transforming growth factor (TGF)β- and mitogen-activated protein kinase-signaling are associated with oxidative stress and DNA damage, and share a phenotype of drug-induced paracrine ‘bystander senescence’ (46). Therefore, miRNAs targeting TGFβ pathways may collaborate to induce and/or maintain this bystander senescence (46). The present miRNA profiling data reveals that DDW may contribute to phenotypic alterations of senescent cells, autophagy, redox homeostasis and mitochondrial metabolism by modulating the expression of key regulatory transcripts (Fig. 5). Further investigation on the effect of miRNA release patterns may elucidate the complex roles of miRNAs in the response to therapy.

In conclusion, the establishment of adjuvant therapy to allow premature senescence of tumor cells may be expressed by the modulation of apoptosis, autophagy, senescent drug resistance or mitochondrial activity miRNA transcripts, thus leading to the activation of specific target genes with important roles in cell fate. Exosomal-released miRNAs represent an effective method to monitor the response to DDW as a possible adjuvant therapy, and to identify novel activated mechanisms associated with drug resistance. Furthermore, DDW may be an adjuvant treatment in colorectal cancer, but a better comprehension of the associated molecular mechanisms will be necessary for developing novel efficient therapeutic strategies, where the transcriptomic pattern serves an important role.

### Table IV. IC_{50} concentrations for 5-FU and oxaliplatin obtained in DLD-1 cells.

| RPMI medium | Cytostatic agent | IC_{50} 24 h (µM) | IC_{50} 48 h (µM) | IC_{50} 72 h (µM) |
|-------------|-----------------|------------------|------------------|------------------|
| SC          | 5-FU            | 7.64             | 4.64             | -                |
|             | Oxaliplatin     | 4.57             | 4.60             | 4.63             |
| DDW         | 5-FU            | 4.42             | 3.74             | 7.30             |
|             | Oxaliplatin     | 21.04            | 4.92             | 6.09             |

IC_{50}, concentration of an inhibitor where the response is reduced by half; 5-FU, 5-fluorouracil; SC, standard conditions; DDW, deuterium-depleted water.

![Figure 4](image-url) Evaluation of senescence in DLD-1 colorectal cell line exposed to a low concentration of deuterium. Cells were cultivated for 13 passages in RPMI-1640 medium in SC or low deuterium, and assessed for expression of β-galactosidase (red arrows), which is present in senescent cells only. A slight activation of senescence was observed in cells cultivated in DDW growth medium. DDW, deuterium-depleted water.

![Figure 5](image-url) miRNAs as key modulators of apoptosis, autophagy, mitochondrial activity drug resistance and senescence. miRNA/miR, microRNA.
Acknowledgements

The authors would like to thank MeCro System SRL (Bucharest, Romania) for providing Qlarivia deuterium-depleted water as part of the GenCanD project.

Funding

The present study is part of the research grant ‘New strategies for improving life quality and survival in cancer patients: Molecular and clinical studies of the tumor genome in deuterium-depleted water treatment augmentation-GenCanD’. The research project was supported by Iuliu-Hataganu University of Medicine and Pharmacy (Cluj-Napoca, Romania; grant no. 128/2014; PN-II-PT-PCCA-2013-4-2166).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

SC, VP and AJ performed the cell culture experiments. LR and LP performed the analyses using the microscope and were responsible for the RNA extraction and quality control. CB performed the microarray study. RCP performed the bioinformatics analysis. CI and IBN were responsible for the study design, and supervising and revising the manuscript. All the authors contributed to the writing of the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Chabner BA and Roberts TG Jr: Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 5: 65-72, 2005.
2. Gibalová L, Sereš M, Rusnák M, Ditte P, Labudová M, Uhrík B, Pastorek J, Seldák J, Breier A and Sulová Z: P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation. Toxicol In Vitro 26: 435-444, 2012.
3. Mahon KL, Henschall SM, Sutherland RL and Horvath LG: Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer 18: R103-R123, 2011.
4. Qu B, Aho KS, Li C, Kang S, Sillanpää M, Yan F and Raymond PA: Greenhouse gases emissions in rivers of the Tibetan Plateau. Sci Rep 7: 16573, 2017.
5. Goncharuk VV, Kavitskaya AA, Romanyukina IY and Loboda OA: Revealing water’s secrets: Deuterium depleted water. Chem Cent J 7: 103, 2013.
6. Kuchner DJ, Baker A and Dunstall TG: Pharmacological uses and perspectives of heavy water and deuterated compounds. Can J Physiol Pharmacol 77: 79-88, 1999.
7. Basov AA, Bykov IM, Baryshev MG, Dzhimak SS and Bykov MI: Determination of deuterium concentration in foods and influence of water with modified isotopic composition on oxidation parameters and heavy hydrogen isotopes content in experimental animals. Vopr Pitan 83: 43-50, 2014 (In Russian).
8. Rehakova R, Klimentova J, Cebova M, Barta A, Matuskova Z, Labas P and Pechanova O: Effect of deuterium-depleted water on selected cardiometabolic parameters in fructose-treated rats. Physiol Res 65 (Supplementum 3): S401-S407, 2016.
9. Cong FS, Zhang YR, Sheng HC, Ao ZH, Zhang SY and Wang YJ: Deuterium-depleted water inhibits human lung carcinoma cell growth by apoptosis. Exp Ther Med 1: 277-283, 2010.
10. Gyöngyi Z, Budán F, Szabó I, Ember I, Kiss I, Krempels K, Somlyai L and Somlyai G: Deuterium depleted water effects on survival of lung cancer patients and expression of Kras, Bcl2, and Msc genes in mouse lung. Nutr Cancer 65: 240-246, 2013.
11. Hartmann J, Bader Y, Horvath Z, Saiko P, Grusch M, Illmer C, Madlener S, Fritzer-Szekeres M, Hefler N, Alken RG and Szekeres T: Effects of heavy water (D2O) on human pancreatic tumor cells. Anticancer Res 25: 3407-3411, 2005.
12. Wang H, Zhu B, He Z, Fu H, Dai Z, Huang G, Li B, Qin D, Zhang X, Tian L, et al: Deuterium-depleted water (DDW) inhibits the proliferation and migration of nasopharyngeal carcinoma cells in vitro. Biomed Pharmacother 67: 489-496, 2013.
13. Bu H, Wedel S, Cavinato M and Jansen-Dürr P: MicroRNA regulation of oxidative stress-induced cellular senescence. Oxid Med Cell Longev 2017: 2398696, 2017.
14. Braicu C, Cojocneau-Petric R, Chiru S, Truta A, Floarea A, Petrut B, Achmas-Cadariu P and Berindan-Neagoe I: Clinical and pathological implications of miRNA in bladder cancer. Int J Nanomedicine 10: 791-800, 2015.
15. Irimie AI, Sonea L, Jurj A, Mehterov N, Zimta AA, Budisan L, Braicu C and Berindan-Neagoe I: Future trends and emerging issues for nanodelivery systems in oral and oropharyngeal cancer. Int J Nanomedicine 12: 4593-4606, 2017.
16. Braicu C, Tomuleasa C, Monroig C, Cucuianu A, Berindan-Neagoe I and Calin GA: EXosomes as divine messengers: Are they the Hermes of modern molecular oncology? Cell Death Differ 22: 34-45, 2015.
17. Ling H, Pickard K, Ivan C, Jussia C, Ikuo M, Mitter R, Spizzo P, Bullock M, Braicu C, Pileczki V, et al: The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut 65: 977-989, 2016.
18. Braicu C, Calin GA and Berindan-Neagoe I: MicroRNAs and cancer therapy-from bystanders to major players. Curr Med Chem 20: 3561-3573, 2013.
19. Geretto M, Pulliero A, Rosano C, Zhabayeva D, Bersimbaev R and Izzotti A: Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. Am J Cancer Res 7: 1350-1371, 2017.
20. Ramalingam S, Subramaniam D and Anant S: Manipulating miRNA expression: A novel approach for colon cancer prevention and chemotherapy. Curr Pharmacol Rep 1: 141-153, 2015.
21. Taranu I, Braicu C, Marin DE, Pistol GC, Motiu M, Balacescu L, Berindan Neagoe I and Burlacu R: Exposure to zearalenone mycotoxin alters in vitro porcine intestinal epithelial cells by differential gene expression. Toxicol Lett 232: 310-325, 2015.
22. Braicu C, Cojocneau-Petric R, Jurj A, Gulei D, Taranu I, Gras AM, Marin DE and Berindan-Neagoe I: Microarray based gene expression analysis of Sus Scrofa duodenum exposed to zearalenone: Significance to human health. BMC Genomics 17: 646, 2016.
23. Pistol GC, Braicu C, Motiu M, Gras MA, Marin DE, Stancu M, Calin L, Israel-Romling F, Berindan-Neagoe I and Taranu I: Zearalenone mycotoxin affects immune mediators, MAPK signalling molecules, nuclear receptors and genome-wide gene expression in pig spleen. PLOS One 10(9): e0127503, 2015.
24. Irimie AI, Braicu C, Pileczki V, Petrushev B, Soritau O, Campian RS and Berindan-Neagoe I: Knocking down of p53 triggers apoptosis and autophagy, concomitantly with inhibition of migration on SNC-4 oral squamous carcinoma cells. Mol Cell Biochem 419: 75-82, 2016.
25. Braicu C, Pileczki V, Irimie A and Berindan-Neagoe I: p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells. Mol Cell Biochem 381: 61-68, 2013.
26. Pileczki V, Braicu C, Gherman CD and Berindan-Neagoe I: TNF-α gene knockout in triple negative breast cancer cell line induces apoptosis. Int J Mol Sci 14: 411-420, 2012.
27. Piechota M, Sunderland P, Wysocka A, Nalberczak M, Sliwinska MA, Radwanska K and Sikora E: Is senescence-associated β-galactosidase a marker of neuronal senescence? Oncotarget 7: 81099-81109, 2016.

28. Krämer A, Green J, Pollard I, Jand Tugendreich S: Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 30: 523-530, 2014.

29. Carrato A: Adjuvant treatment of colorectal cancer. Gastrointest Cancer Res 2 (4 Suppl): S42-S46, 2008.

30. Berrendin-Neagoe I, Braicu C, Piletzki V, Cojocneau Petric R, Miron N, Balacescu O, Iancu D and Culeanu T: 5-Fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells. J Gastrointestin Liver Dis 22: 37-43, 2013.

31. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T and Hashimoto-Tamaoki T: Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: A novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61: 1029-1037, 2001.

32. Braicu C, Tudoran O, Balacescu L, Catana C, Neagoe E, Berrendin-Neagoe I and Ionescu C: The significance of PDGF expression in serum of colorectal carcinoma patients-correlation with Duke's classification. Can PDGF become a potential biomarker? Chirurgia (Bucur) 108: 849-854, 2013.

33. Berrendin-Neagoe I, Catana C, Calin GA and Berrendin-Neagoe I: NCRNA combined therapy as future treatment option for cancer. Curr Pharm Des 20: 6565-6574, 2014.

34. Benson AB III, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger FC, Fenton MJ, Fuchs CS, et al.: Colon cancer, version 3.2014. J Natl Compr Canc Netw 12: 1028-1059, 2014.

35. Campisi J: Aging, cellular senescence, and cancer. Annu Rev Physiol 75: 685-705, 2013.

36. Cerella C, Grandjentnée C, Dicato M and Diedrich M: Roles of apoptosis and cellular senescence in cancer and aging. Curr Drug Targets 17: 405-415, 2016.

37. Roninson IB: Tumor cell senescence in cancer treatment. Cancer Res 63: 2705-2715, 2003.

38. Ewald JA, Desotelle JA, Wilding G and Jarrard DF: Therapy-induced senescence in cancer. J Natl Cancer Inst 102: 1536-1546, 2010.

39. Zhao Y, Wu D, Fei C, Guo J, Gu S, Zhu Y, Xu F, Zhang Z, Wu L, Li X and Chang C: Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome. Haematologica 100: 194-204, 2015.

40. Gorospe M and Abdelmohsen K: MicroRegulators come of age in senescence. Trends Genet 27: 233-241, 2011.

41. Gibbings D, Mostowy S, Jay F, Schwab Y, Cossart P and Voinnet O: Selective autophagy degrades DICER and AGO2 and regulates miRNA activity. Nat Cell Biol 14: 1314-1321, 2012.

42. Bian XJ, Zhang GM, Gu CY, Cai Y, Wang CF, Shen YJ, Zhu Y, Zhang HL, Dai B and Ye DW: Down-regulation of Dicer and Ago2 is associated with cell proliferation and apoptosis in prostate cancer. Tumour Biol 35: 11571-11578, 2014.

43. Prodromaki E, Korpetinou A, Giannopoulou E, Vlentinou E, Chatziathanasiadou M, Papachristou NI, Scopa CD, Papadaki H, Kalofonos HP and Papachristou DF: Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas. Cell Oncol (Dordr) 38: 307-317, 2015.

44. Gibbings D, Mostowy S and Voinnet O: Autophagy selectively regulates miRNA homeostasis. Autophagy 9: 761-783, 2013.

45. Grootaert MO, da Costa Martins PA, Bitsch N, Pintelon I, De Meyer GR, Martinet W and Schrijvers DM: Defective autophagy in vascular smooth muscle cells accelerates senescence and promotes neoindima formation and atherogenesis. Autophagy 11: 2014-2032, 2015.

46. Hubbackova S, Krejciakova K, Bartek J and Hodyz Z: ILL1- and TGFβ-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine ‘bystander senescence’. Aging (Albany NY) 4: 932-951, 2012.